Skip to content

Laryngeal Mask in Upper Gastrointestinal Procedures

Anesthesiological Management of Ventilation With Laryngeal Mask in Patients Undergoing Endoscopic Retrograde Cholangiopancreatography (ERCP) and Endoscopic Ultrasound Procedures

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03567928
Acronym
SeoMask
Enrollment
16
Registered
2018-06-26
Start date
2018-09-26
Completion date
2019-04-10
Last updated
2019-04-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Airway Device, Anesthesia, C.Surgical Procedure; Gastrointestinal

Brief summary

Diagnostic and operative procedures of upper gastrointestinal (GI) tract are very common in all patients. Some procedures are difficult to tolerate because of long duration, prone position or significant stimulation of the upper airways. An example are endoscopic retrograde cholangiopancreatography (ERCP) and endoscopic pancreatic ultrasound. The procedures are generally performed with deep sedation. Many pharmacologic regimens are available and described in literature. The investigator's institute adopts propofol target controlled infusion (TCI), which usually guarantees unconsciousness and unresponsiveness of patients. The main adverse event is dose-related respiratory depression. Pre-existing reasons for hypoventilation can exacerbate this event, especially in the elderly and the chronic obstructive pulmonary disease-patients. Laryngeal mask (LMA) is a useful tool to apply a pressure support ventilation. One specific type of LMA allows to separate the gastric and respiratory tract and, allows the anesthesiologist to support patient's ventilation as (and only if) necessary.

Detailed description

This is a monocentric randomized controlled trial of superiority of LMA use in GI endoscopic procedures. Randomization is centralized. The study is single blind (patient). The study is no-profit. Every patients undergoing scheduled ERCP and endoscopic ultrasound will be screened and consecutive eligible patients will be enrolled. Subjects will be allocated according to a simple randomization list. The study starts after randomization and ends after discharge from the recovery room. After peripheral venous catheter insertion and vital parameters monitoring, patients will receive propofol TCI with a tailored target between 4 and 6 mcg/ml. The treatment group will receive LMA insertion and End-Tidal Carbon Dioxide (ETCO2) monitoring throughout the procedure. In case of hypoventilation, with an ETCO2 above 50 mmHg, the patient will be supported as necessary with PSV. The control group will not receive any airway device, according to the standard treatment. At the end of the procedure, both group will receive a laboratory testing (peripheral arterial sample), when the patient is still sedated. Vital parameters monitoring will continue in recovery room. Patients will be discharge as usual with an Aldrete score \> 9. Data will be collected during the procedure and in recovery room. Data will be stored in electronic database without mention to patient's name.

Interventions

DEVICESedation with Gastro Cuff Pilot Laryngeal Mask

This specific type of laryngeal mask allows to separate the gastric and respiratory tract and allows the anesthesiologist to support patient's ventilation as (and only if) necessary.

DRUGPropofol

Target controlled infusion (TCI) with propofol

Sponsors

Ospedale San Raffaele
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Masking description

Induction of anesthesia and subsequent use (or not) of the device (laryngeal mask)

Intervention model description

Two groups: one receive sedation in spontaneous breathe, the other receive sedation with laryngeal mask

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* age \>18 years * written informed consent * elective ERCP and endoscopic ultrasound procedure

Exclusion criteria

* pregnancy * contraindication to propofol administration * contraindication to mask insertion (e.g. malformation) * emergency operation (not scheduled) * preexisting causes of hypoventilation (e.g. chronic obstructive pulmonary disease, neuromuscular disease…)

Design outcomes

Primary

MeasureTime frameDescription
Partial Pressure of Carbon Dioxide (PaCO2)Just before patient awakening (approximately 90-120 min after induction of anesthesia)PaCO2 level assessed by arterial sample

Secondary

MeasureTime frameDescription
Satisfaction of the patient20 minutes after patient awakeningSatisfaction of the patient assessed by a Likert 5 points-scale: 1 Strongly disagree; 2 Disagree; 3 Neutral/Neither agree nor disagree; 4 Agree; 5 Strongly agree
Number of pressure support ventilation in treatment groupDuring the procedureNumber needing pressure support ventilation (PSV) in the treatment group. A PSV will be performed in case of End-Tidal carbon dioxide level raising above 50 mmHg.
pHJust before patient awakening (approximately 90-120 min after induction of anesthesia)pH assessed by arterial sample
Satisfaction of the procedure operator1 minute after patient awakeningSatisfaction of the operator assessed by a Likert 5 points-scale: 1 Strongly disagree; 2 Disagree; 3 Neutral/Neither agree nor disagree; 4 Agree; 5 Strongly agree
Time to recover after the procedureDuring recovery room stay (approximately 15-45 min after patient awakening)Time needed to recover: from arrival in recovery room to a Aldrete Score \> 9
Number of completed endoscopic proceduresDuring the procedureNumber of completed endoscopic procedures without necessity to change anesthesiological treatment or postpone the procedure for any reason
Partial Pressure of Oxygen (PaO2)Just before patient awakening (approximately 90-120 min after induction of anesthesia)PaO2 level assessed by arterial sample

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026